14 Sep 2017

(13 votes)

How You Can Benefit From Rigvir® for Glioblastoma: Brief History and Recent Studies

The latest published studies in Melanoma Research, a medical journal, dated October 2015, claim that Rigvir® is able to raise the survival rates of virotherapy patients 4.39–6.57-fold [1]. Now you may be asking yourself about the reasons for such success rate. Let’s find out.

oncolytic virotherapy glioblastoma

A patient is getting ready to receive Rigvir® injection

Riga virus (Rigvir®) was designed in the middle of the 20th century by Aina Muceniece, an immunologist from Latvia. She discovered ECHO-7 virus in babies digestive system, and it became the key component of Rigvir®. The invention of the drug marked an advent of a new cancer treatment method, virotherapy, which is fully based on applying oncolytic viruses.

At the beginning, the medicine targeted only melanoma patients – they were the first to receive the treatment. Shortly after that, the clinical experience showed that Rigvir® is able to help fight the following types of cancer:

  • Bladder cancer
  • Kidney cancer
  • Uterine and ovarian cancer
  • Breast cancer
  • Brain cancer
  • Several kinds of sarcoma
  • Prostate cancer etc.

Wondering about how Rigvir® fights tumours? It’s that simple: the medicine is injected into your body detecting malignant cells. Then oncotropism takes place – the process of penetrating inside a cell. Once inside, Rigvir® eliminates the cancer cell and travels to another one killing the entire tumor.

A unique feature of Rigvir® is almost no side effects. The only after-effect reported was a temperature rise up to 37.5°C/99.5°F that lasted for 3 days. Another reason why an increasing number of cancer patients refer to Rigvir® is that it leaves your healthy cells untouched. This means virotherapy may be applied as the only cancer treatment option as well as a supplement to radiotherapy or chemo.

If you decide to go for virotherapy to treat glioblastoma, note that Rigvir® is registered only in 3 states: Latvia (2004), Georgia (2015), and Armenia (2016). Latvia remains the prominent direction for Rigvir® treatment with Global Virotherapy Cancer Clinic being the most frequently visited virotherapy clinic throughout Europe.

Before applying, please prepare your medical documentation. This is necessary for the oncologists can first evaluate your case at no charge to see if you qualify for Rigvir® therapy. The assessment takes from 48 to 72 hours while the list of your medical files to be provided normally includes:

  • Histopathological findings
  • Cytological observations
  • Recent blood count, including white blood cells
  • Epicrisis
  • MRI or CT
  • Analysis for ALT and creatinine

On receiving the confirmation of your candidacy for Rigvir® therapy, you’ll also receive further details so you can start planning your trip to Latvia for treatment purposes.

Qualification for Virotherapy for Glioblastoma in Latvia: Choose Complex, Onsite, or Remote Package

On average, the virotherapy takes up to 3 years. Most cross-border patients begin the treatment process with 7-day Complex Virotherapy Service Package, which takes place in sunny Jurmala, Latvia. The Global Virotherapy Cancer Clinic situated there welcomes patients from all over the world serving as a virotherapy hub. When you arrive in Latvia, an English-speaking driver will pick you up at the airport and drive you to the clinic.

Your 7-day Complex Virotherapy Service Package consists of:

  • Tests if you are allergic to Rigvir®
  • 3 Rigvir® injections
  • Personalised set of meals with regard to your health condition
  • Comfortable accommodation of your choice – standard or superior lodging
  • Daily consultations with doctors
  • 24/7 support of medical and administrative staff
  • Consultations with a psychologist, physiotherapist, art therapist, and so on
  • Detailed 3-month follow-up plan to maintain your treatment process

Spending such an intense week at the virotherapy clinic in Latvia costs EUR 7,000 if you stay in a standard room or EUR 10,000 in case you pick a superior one (it offers a Jacuzzi and a terrace).

oncolytic virotherapy glioblastoma oncolytic virotherapy glioblastoma oncolytic virotherapy glioblastomaoncolytic virotherapy glioblastomaoncolytic virotherapy glioblastomaoncolytic virotherapy glioblastoma

When you fly back home, you should continue your 3-month follow-up program as part of the package. Up to 11 Rigvir® vials may be recommended by your oncologist in Latvia. Please remember that they are purchased separately.

Once you complete your Complex Virotherapy Service Package, there are two options to choose from if you wish to continue your Rigvir® treatment: Onsite Follow-Up Package or Remote Follow-Up Package.

Onsite Follow-Up Package   Remote Follow-Up Package
 Staying in Latvia for 3 days  Staying at home
 Daily consultations with the doctors  30-minute Skype conference with an oncologist
 1 session with art therapist, psychologist or another specialist at your choice  Monthly support by the doctors
Personal nutrition plan
 Development of 3-month plan for further treatment 


List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.